Do beta-adrenoceptor blocking drugs cause retroperitoneal fibrosis?

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• The etiology of retroperitoneal fibrosis (RPF) is largely unknown.
• Various medications, including beta-adrenoceptor blocking agents, have been implicated as potential causes of RPF.
• Understanding potential drug-induced causes is crucial for patient management and diagnosis.

Purpose of the Study:

• To investigate the potential causal role of beta-adrenoceptor blocking agents in the development of retroperitoneal fibrosis.
• To analyze the association between antihypertensive drug use and the onset or progression of RPF.

Main Methods:

• Retrospective review of 100 hospital inpatients diagnosed with retroperitoneal fibrosis.
• Analysis of patient records to determine symptom onset, pre-diagnosis medication history (including beta-adrenoceptor blocking agents), and admission blood pressure.
• Assessment of drug use patterns in relation to RPF diagnosis and long-term outcomes.

Main Results:

• A significant proportion of patients had hypertension (diastolic BP ≥ 90 mm Hg) at admission, often despite antihypertensive treatment.
• Only a small number of patients received beta-adrenoceptor blocking agents prior to RPF symptom onset.
• Several patients continued beta-adrenoceptor blocking agents long-term post-diagnosis without RPF recurrence, suggesting no causal link.

Conclusions:

• The findings suggest that beta-adrenoceptor blocking agents are unlikely to be a cause of retroperitoneal fibrosis.
• Antihypertensive medications, including beta-blockers, were likely used to treat pre-existing or associated hypertension rather than causing RPF.
• Further research may clarify the unknown etiology of retroperitoneal fibrosis.